医薬品の承認後規制の課題への対応:独立した第三者評価の必要性
Itai Bavli1, Yair Sadaka2, Chen Yanover3
1Interdisciplinary Studies Unit, The Graduate Program in Science, Technology and Society, Bar-Ilan University, Ramat Gan, Israel; School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.
No abstract available in PubMed .
さらに関連する動画
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
関連する概念動画
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
FDA Approved Drugs: Changes to Approved Drugs
Drug Products: Biologics, Biosimilars and Interchangeables
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
